Scarica l'app Stockscreener
19.82
42.58%
-14.70
Dopo l'orario di chiusura:
20.00
0.18
+0.91%
Precedente Chiudi:
$34.52
Aprire:
$22.24
Volume 24 ore:
1.99M
Relative Volume:
9.51
Capitalizzazione di mercato:
$293.90M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-72.29%
1M Prestazione:
-63.57%
6M Prestazione:
-40.50%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$18.94
$23.79
Intervallo di 1 settimana:
$18.94
$49.37
Portata 52W:
$15.19
$74.49
Neurogene Inc Stock (NGNE) Company Profile
Nome
Neurogene Inc
Settore
Industria
Telefono
(877) 237-5020
Indirizzo
535 W 24TH STREET, NEW YORK
Confronta NGNE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| NGNE | 19.82 | 293.90M | 0 | 0 | 0 | 0.00 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Neurogene Inc Borsa (NGNE) Ultime notizie
Neurogene: Q3 Earnings Snapshot - San Antonio Express-News
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neurogene Inc.NGNE - PR Newswire
Neurogene Inc (NGNE) Quarterly 10-Q Report - Quartzy
Neurogene Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Neurogene Reports Promising Rett Syndrome Trial Data Despite Wider Q3 Loss | NGNE Stock News - StockTitan
Stock Market News: QMMM Holdings plunges by 69% whereas Neurogene falls by 44.05% during mid day trading - Business Upturn
Bronstein, Gewirtz & Grossman, LLC Is Investigating Neurogene Inc. (NGNE) And Encourages Stockholders to Connect - AccessWire
Neurogene, Nvidia And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Neurogene stock plunges 36% on NGN-401 study update (NASDAQ:NGNE) - Seeking Alpha
Neurogene falls again on Rett gene therapy side effects - pharmaphorum
Neurogene Drops High-Dose Cohort of Gene-Therapy Study for Rett Syndrome - MarketWatch
Neurogene Adjusts NGN-401 Trial After Adverse Event - TipRanks
Neurogene Halts High-Dose Rett Syndrome Trial After Critical Safety Event, FDA Clears Low Dose | NGNE Stock News - StockTitan
Neurogene Inc. (NGNE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - AccessWire
Neurogene Inc. (NASDAQ:NGNE) Given Average Recommendation of "Buy" by Analysts - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Neurogene Inc. (NGNE) and Encourages Stockholders to Learn More About the Investigation - AccessWire
Neurogene To Report Rett Syndrome Trial Data Next WeekStock Up 90% In 8 Months - RTTNews
Janus Henderson Group PLC's Strategic Reduction in Neurogene Inc Holdings - GuruFocus.com
United States shares lower at close of trade; Dow Jones Industrial Average down 0.86% - MSN
Bronstein, Gewirtz & Grossman, LLC Encourages Neurogene Inc. (NGNE) Investors to Inquire about Securities Investigation - AccessWire
RTW INVESTMENTS, LP Expands Stake in Neurogene Inc - GuruFocus.com
Neurogene Stock Plummets 44%: Is All Hope Lost for This Biotech?" - MarketBeat
Neurogene (NASDAQ:NGNE) Stock Price Expected to Rise, Stifel Nicolaus Analyst Says - Defense World
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Neurogene Inc. (NGNE) And Encourages Investors to Reach Out - AccessWire
Neurogene’s NGN-401 gene therapy scores well in Rett syndrome - The Pharma Letter
Top 1% Biotech Neurogene Crashes, Wiping Out A Run, On A Serious Side Effect - MSN
FMR LLC Expands Stake in Neurogene Inc - GuruFocus.com
Neurogene shares target lifted, outperform on positive data By Investing.com - Investing.com Australia
Neurogene stock target up as Stifel notes consistent efficacy despite emerging safety concerns - Investing.com Canada
Neurogene’s Rett Data Draw Optimism Despite Serious Adverse Event - Citeline
Neurogene Gene Therapy Shows Signs of Efficacy in Small Study, But an Adverse Event Spooks Investors - MedCity News
Neurogene stock target cut, reiterates outperform on trial results By Investing.com - Investing.com Canada
U.S. Stock market top losers: Neurogene Inc. declines by 46.04% while Pagaya Technologies falls by 34.87% during mid day trading - Business Upturn
U.S. Stock market: BTC Digital(+314.68%), BTCS Inc.(+35.64%), Neuronetics(−41.36%) among most volatile stocks during mid day trading - Business Upturn
Neurogene shares target lifted, outperform on positive data - Investing.com
Neurogene shares fall on Rett syndrome gene therapy data - pharmaphorum
Neurogene hits a setback in the clinic, days after fundraise - BioPharma Dive
Neurogene Stock Tanks After Adverse Event In Early-Stage Rett Syndrome Gene Therapy Trial - Benzinga
Neurogene Reports Promising Interim Results for NGN-401 Trial - TipRanks
U.S. Stock market top losers: Pagaya Technologies drops by 31.44%, Rockwell Medical declines by26.24% in early trading - Business Upturn
Leerink Partners Forecasts Strong Price Appreciation for Neurogene (NASDAQ:NGNE) Stock - MarketBeat
U.S. Stock market most volatile stocks: Neuronetics(-47.27%), Heron Therapeutics(-20.15%) and LogicMark(+94.36%) in early trading - Business Upturn
Neurogene (NASDAQ:NGNE) Price Target Raised to $55.00 at HC Wainwright - MarketBeat
Robert W. Baird Increases Neurogene (NASDAQ:NGNE) Price Target to $72.00 - MarketBeat
Neurogene Shares Tank After Adverse Event Linked to Early-Stage Rett Syndrome Gene Therapy - BioSpace
Neurogene Shares Drop 35% on Rett Syndrome Gene Therapy Trial Da - GuruFocus.com
Neurogene Shares Drop 35% on Rett Syndrome Gene Therapy Trial Data - Yahoo Finance
Neurogene’s stock sinks after adverse event with Rett syndrome gene therapy - Clinical Trials Arena
Neurogene reports promising Rett syndrome trial data By Investing.com - Investing.com South Africa
Neurogene reports promising Rett syndrome trial data - Investing.com India
Neurogene plummets 35% on gene therapy trial data for Rett syndrome - Seeking Alpha
Neurogene Inc Azioni (NGNE) Dati Finanziari
Non sono disponibili dati finanziari per Neurogene Inc (NGNE). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
3.66%
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):